CLINICAL AND SEROLOGICAL RESPONSES FOLLOWING PRIMARY AND BOOSTER IMMUNIZATION WITH SALMONELLA-TYPHI-VI CAPSULAR POLYSACCHARIDE VACCINES
CLINICAL AND SEROLOGICAL RESPONSES FOLLOWING PRIMARY AND BOOSTER IMMUNIZATION WITH SALMONELLA-TYPHI-VI CAPSULAR POLYSACCHARIDE VACCINES
复制标题
DOI：
10.1016/0264-410x(94)90194-5
复制
发表时间：
1994-03-01
期刊：
影响因子：
5.5
通讯作者：
ROBBINS, JB
中科院分区：
文献类型：
--
作者：
KEITEL, WA;BOND, NL;ROBBINS, JB
采用双盲方法对肌肉注射两种伤寒沙门菌荚膜多糖（Vi）后的临床和血清抗体反应进行了评估。健康成人被随机分配接受25 μ g剂量的液体（Vi- liq, n = 182）或冻干Vi疫苗（Vi- lyoph, n = 55）或安慰剂（n = 86）。13/182（7%）的Vi-Liq和3/55（5%）的Vi-Lyoph受者在注射部位出现直径大于或等于1cm的红斑和/或硬结（无统计学意义，n.s）。发烧（口腔温度大于或等于100华氏度（37.8摄氏度））发生在
Clinical and serum antibody responses following intramuscular injection of two formulations of Salmonella typhi Vi capsular polysaccharide (Vi) were assessed in a double-blind evaluation. Healthy adults were randomly assigned to receive a 25 mu g dose of liquid (Vi-Liq, n = 182) or freeze-dried Vi vaccine (Vi-Lyoph; n = 55), or placebo (n = 86). Erythema and/or induration greater than or equal to 1 cm in diameter at the injection site developed in 13/182 (7%) of Vi-Liq and 3/55 (5%) of Vi-Lyoph recipients (not significant, n.s.). Fever (oral temperature greater than or equal to 100 degrees F(37.8 degrees C)) occurred in